CA2233687A1 - Nouvelles methodes diagnostiques de carcinome prostatique - Google Patents
Nouvelles methodes diagnostiques de carcinome prostatique Download PDFInfo
- Publication number
- CA2233687A1 CA2233687A1 CA 2233687 CA2233687A CA2233687A1 CA 2233687 A1 CA2233687 A1 CA 2233687A1 CA 2233687 CA2233687 CA 2233687 CA 2233687 A CA2233687 A CA 2233687A CA 2233687 A1 CA2233687 A1 CA 2233687A1
- Authority
- CA
- Canada
- Prior art keywords
- psa
- cap
- patient
- total
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 201000005825 prostate adenocarcinoma Diseases 0.000 title claims abstract description 9
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims abstract description 148
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims abstract description 148
- 238000001574 biopsy Methods 0.000 claims abstract description 32
- 210000002307 prostate Anatomy 0.000 claims abstract description 26
- 210000004369 blood Anatomy 0.000 claims abstract description 17
- 239000008280 blood Substances 0.000 claims abstract description 17
- 210000002966 serum Anatomy 0.000 claims abstract description 16
- 238000003745 diagnosis Methods 0.000 claims description 9
- 238000003556 assay Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 8
- 208000017497 prostate disease Diseases 0.000 description 7
- TYDSIOSLHQWFOU-UHFFFAOYSA-N 2-cyclohexylidenecyclohexan-1-one Chemical compound O=C1CCCCC1=C1CCCCC1 TYDSIOSLHQWFOU-UHFFFAOYSA-N 0.000 description 3
- 208000025844 Prostatic disease Diseases 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 101100096703 Drosophila melanogaster mtSSB gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100070104 Mus musculus Hacl1 gene Proteins 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention porte sur une méthode diagnostique de carcinome prostatique (CAP) chez un sujet humain sans recours à une biopsie. On mesure tout d'abord le niveau total d'antigène prostatique spécifique (PSA) présent dans le sang ou le sérum du sujet. Si le sujet a un niveau total de PSA compris entre 2,5 ng/ml et 20,2 ng/ml, on mesure alors le niveau libre de PSA présent dans le sang ou le sérum du sujet, puis on calcule le rapport entre PSA libre (10) et PSA total (12). Si ce rapport est inférieur à environ 7 %, le diagnostic est que le sujet présente un CAP. Ladite méthode peut également être utilisée chez des sujets ayant un PSA total d'au moins 10,1 ng/ml, mais pour lesquels une biopsie de la prostate a été négative.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/536,215 US5710007A (en) | 1995-09-29 | 1995-09-29 | Methods for diagnosing prostatic adenocarcinoma |
| US08/536,215 | 1995-09-29 | ||
| PCT/US1996/015586 WO1997012245A1 (fr) | 1995-09-29 | 1996-09-27 | Nouvelles methodes diagnostiques de carcinome prostatique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2233687A1 true CA2233687A1 (fr) | 1997-04-03 |
Family
ID=29405951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2233687 Abandoned CA2233687A1 (fr) | 1995-09-29 | 1996-09-27 | Nouvelles methodes diagnostiques de carcinome prostatique |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2233687A1 (fr) |
-
1996
- 1996-09-27 CA CA 2233687 patent/CA2233687A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5698402A (en) | Methods for diagnosing benign prostatic hyperplasia | |
| US5710007A (en) | Methods for diagnosing prostatic adenocarcinoma | |
| Paterson et al. | A radioimmunoassay for the detection of a human tumor‐associated glycoprotein (tag‐72) using monoclonal antibody B72. 3 | |
| Murphy et al. | Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer | |
| CA2760569A1 (fr) | Nouveau cocktail d'anticorps | |
| EP2403875A1 (fr) | Anticorps monoclonaux de la glycodeline et leurs procedes d'utilisation dans la detection du cancer de l'ovaire | |
| US5994085A (en) | Methods and devices for detecting non-complexed prostate specific antigen | |
| US20120252040A1 (en) | Kit for diagnosing prostate cancer and diagnosis method | |
| US20060211059A1 (en) | Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone | |
| JP4364437B2 (ja) | 腺癌または良性の前立腺の病状を診断する方法 | |
| Beastall et al. | A review of the role of established tumour markers | |
| EP1418434A2 (fr) | Analyse enzymatique non invasive d'états associés au remodelage d'un tissu | |
| US20030215900A1 (en) | Non-invasive enzyme screen for cancer | |
| WO1999013335A1 (fr) | Diagnostic des affections prostatiques benignes et de l'adenome prostatique | |
| Thriveni et al. | Correlation study of Carcino Embryonic Antigen & Cancer Antigen 15.3 in pretreated female breast cancer patients | |
| US7015005B2 (en) | Methods and devices for detecting non-complexed prostate specific antigen | |
| Milford Ward | Tumour markers | |
| MXPA98002404A (en) | Novedous methods to diagnose adenocarcinoma prostat | |
| CA2938809C (fr) | Composition et procede pour detecter une maladie neoplasique maligne | |
| KR20200080183A (ko) | 치주질환 진단 방법, 이를 위한 조성물 및 키트 | |
| WO1997039351A1 (fr) | Nouveaux procedes de prediction et de detection precoce de l'adenome prostatique | |
| CN111208304B (zh) | 肿瘤来源IgG在甲状旁腺癌诊断和预后中的用途 | |
| Tiffen et al. | Ovarian cancer screening: are there any options? | |
| MXPA97006415A (es) | Novedosos metodos para diagnosticar enfermedades prostaticas benignas | |
| Kobayashi et al. | Clinical evaluation of new cancer-associated antigen CA125 II in epithelial ovarian cancers: Comparison with CA125 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |